睿知中国医院研究地图
候选清单

正在招募β 地中海贫血I期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

A Multiple Ascending Dose Study of 9MW3011 in Patients With Non-transfusion-dependent β-thalassemia

ClinicalTrials.gov 上登记的一项β 地中海贫血开放试验。牵头方不是本站收录的医院;本站收录的 2 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月13日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 2

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 研究中心广西医科大学第一附属医院First Affiliated Hospital of Guangxi Medical University南宁医院页面
  2. 研究中心海南医学院附属医院/海南省人民医院Hainan General Hospital / Hainan Medical University hospitals海口医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT06772766,读取于 2026年11月13日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 5

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(5 项)收起清单
  1. 18 岁 至 65 岁;性别:不限

    登记记录的入选字段

  2. Subjects have New York Heart Association (NYHA) Class III-IV heart failure and other cardiovascular diseases within 6 months prior to screening or currently present

    排除标准第 6 条

  3. Subject must have performance status: Eastern Cooperative Oncology Group (ECOG) performance score of 0 to 1

    入选标准第 6 条

  4. Subjects must have a baseline hemoglobin level between 70-100 g/L(inclusive), based on 2 consecutive measurements taken at least 1 week apart within 4 weeks before randomization

    入选标准第 4 条

  5. Pregnant or lactating women

    排除标准第 15 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;既往治疗;影像与可测量病灶;试验排除的其他疾病。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06772766,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Male and female subjects aged 18 to 65 years (inclusive)
  2. Subject must have a documented genetic diagnosis of β-thalassemia or hemoglobin E/ β-thalassemia
  3. Subjects must meet the criteria for non-transfusion-dependent thalassemia
  4. Subjects must have a baseline hemoglobin level between 70-100 g/L(inclusive), based on 2 consecutive measurements taken at least 1 week apart within 4 weeks before randomization
  5. Subjects must have evidence of iron overload during screening
  6. Subject must have performance status: Eastern Cooperative Oncology Group (ECOG) performance score of 0 to 1
  7. Subjects must fully understand the study procedures and methods, voluntarily participate in the trial, and sign an informed consent form

排除标准:Exclusion Criteria:

  1. Subjects diagnosed with alpha-thalassemia
  2. Subjects diagnosed with HbS/beta-thalassemia or transfusion-dependent beta-thalassemia
  3. Subjects exhibit severe iron overload at the time of screening
  4. In addition to thalassemia, subjects have any other forms of anemia and hematological disorders that the investigator assesses may compromise safety or influence study outcomes
  5. Combined with any significant systemic diseases or psychiatric disorders
  6. Subjects have New York Heart Association (NYHA) Class III-IV heart failure and other cardiovascular diseases within 6 months prior to screening or currently present
  7. During the screening or baseline period, subjects exhibiting a QTcF interval of ≥450ms for males and ≥470ms for females on a 12-lead electrocardiogram (ECG), or presenting an abnormal 12-lead ECG with clinical significance
  8. Uncontrolled hypertension before screening
  9. A history of malignant neoplasm occurring within the last five years
  10. Severe infection requiring hospitalization or intravenous antimicrobial therapy, or uncontrolled systemic bacterial, fungal, or viral active infection
  11. Subject have received concomitant treatment that was not permitted by the protocol
  12. Subjects whose hematological parameters did not meet the inclusion criteria during screening
  13. Subjects with a history of substance abuse, as well as those who yield positive results on substance abuse screening
  14. Subjects who are unable to undergo MRI scans
  15. Pregnant or lactating women
  16. Subjects presenting any other factors deemed unsuitable for participation assessed by the investigator

引自 ClinicalTrials.gov, NCT06772766, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06772766,读取于 2026年11月13日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT06772766